Encyclopedia

A three-peptide vial sold by research-peptide vendors as a simpler, KPV-free variant of the Klow blend, combining a copper peptide with two tissue-repair peptides; marketed for recovery, wound healing, and skin/collagen support.

Rationale

GHK-Cu is included primarily for its collagen-synthesis and wound-healing signaling. BPC-157 and TB-500 are frequently combined with each other on their own (see the tb-500-bpc-157 research pairing) for proposed complementary tissue-repair mechanisms. There are no controlled trials evaluating this three-peptide combination as a whole — the rationale here is inferred from each peptide's individual, largely preclinical mechanism, not from data on the blend itself.

5 : 1 : 1 — GHK-Cu : BPC-157 : TB-500

Multiple independent research-peptide vendors list a 70mg vial containing 50mg GHK-Cu, 10mg BPC-157, and 10mg TB-500 (a 5:1:1 ratio by mass). This figure was consistent across every vendor listing checked; some vendors also offer smaller vial sizes (e.g. 30mg) at the same ratio. No manufacturer-published label or independent third-party lab panel breakdown of actual vial content was available to verify it independently.

Source

Vendor Listing

Commonly Sold As

70mg

Sources

• https://peptide.partners/product/glow-blend-bpc-157-tb-500-ghk-cu/
• https://biolongevitylabs.com/product/glow-blend-ghk-cu-bpc-157-tb-500/
• https://licensedpeptides.com/product/bpc157-tb500-ghk-cu-glow-blend-70mg-vial/

• GHK-Cu

  5 parts

  Copper peptide included for collagen-synthesis, wound-healing signaling, and skin/dermal support; the majority component by mass in this blend.

  Topical cosmetic formulations (concentration in product)

  Dose

  0.05–2 % w/w

  Frequency

  1-2x daily (per product)

  Anecdotal systemic/injectable use — NOT validated

  Dose

  1–2 mg

  Frequency

  daily (anecdotal)

• BPC-157

  1 part

  Proposed gastroprotective and angiogenic peptide via nitric-oxide pathway signaling; one of the most frequently stacked research peptides.

  Rat tendon/ligament injury models (intraperitoneal, once daily)

  Dose

  10 mcg/kg

  Frequency

  once daily

  Reported human intra-articular case observations (knee)

  Dose

  2–4 mcg

  Frequency

  unspecified

• TB-500

  1 part

  Proposed to promote cell migration and angiogenesis via actin sequestration (thymosin beta-4 fragment).

  Animal wound-healing / cardiac studies (full-length Tβ4, systemic)

  Frequency

  varies

  Commonly cited community/clinic loading pattern (TB-500 fragment) — NOT validated

  Dose

  2–2.5 mg

  Frequency

  1-2x weekly (anecdotal)